International Clinical Trials (ICT): Panthera interview

International Clinical Trials (ICT): Panthera interview – Private vs public vaccine studies, how SMOs can secure the future of UK clinical trials Panthera’s Ian Smith and Chris Dodd recently spoke to ICT about the differences in private versus public clinical trials, how speed is key in preclinical processes and how the UK can improve its …

Read more

Panthera contributes to Lord O’Shaughnessy’s independent review into UK clinical trials

Lord James O’Shaughnessy, former Health Minister, has been appointed by the UK government to conduct an independent review of the country’s commercial clinical trials landscape. The review will advise on how to resolve key challenges in conducting commercial clinical trials and ensure that the UK remains a global leader in the field. Lord O’Shaughnessy’s advice is expected to be published this spring.

Panthera Biopartners raises £10 million to accelerate its dedicated clinical trial site expansion

Panthera Biopartners raises £10 million to accelerate its dedicated clinical trial site expansion across the UK and Western Europe Panthera Biosciences (Panthera) has secured £10 million of investment from BGF and Gresham House Ventures, the latter investing on behalf of the Baronsmead VCTs. This investment will allow Panthera to further grow its network of dedicated …

Read more

Valneva vaccine clinical trial, phase 3 results

Valneva have released results from their phase 3 vaccine study (VLA2001). Stating that the trial has successfully met both co-primary end points. This trial compared the efficacy and effectiveness of the Valneva Covid-19 vaccine against the AstraZeneca vaccine. A total of 4012 people, aged 18 years and above were recruited to this clinical trial, across …

Read more

Panthera becomes the world’s first clinical trial site to administer Valneva’s inactivated COVID-19 vaccine to volunteers in COVID prevention study

This month we have been busy vaccinating volunteers in North Manchester, Preston and North London for a new COVID prevention study. It has been an exciting time as we were the world’s first clinical trial site to administer the vaccine to volunteers in this study. The first participant to be vaccinated at our Rochdale clinic …

Read more

Clinical trial specialist Panthera Biopartners has appointed corporate financier Christopher Steed as a non-executive director to continue its expansion both in the UK and overseas

Independent clinical trial site management organisation (SMO), Panthera Biopartners, has appointed M&A and fundraisings adviser Chris Steed as a non-executive director. Chris has over 25 years’ experience as a corporate financier, working at Arthur Andersen, Deloitte and for the past 17 years as Founder and Managing Partner of Argyll Partners. Chris has acted as lead advisor …

Read more

Panthera adapts for COVID-19 virus – Letter from Stuart Young, CEO

As we all continue to adapt to the COVID-19 pandemic, we at Panthera are closely monitoring this rapidly evolving situation as well as remaining vigilant to support our patients and the NHS in any way we can. Panthera sites will remain open for business with significant additional precautions to prevent transmission of the COVID-19 virus. …

Read more